DE60023667D1 - C-terminale kpv polypeptiddimere und deren verwendung zur behandlung von urogenitale störungen - Google Patents

C-terminale kpv polypeptiddimere und deren verwendung zur behandlung von urogenitale störungen

Info

Publication number
DE60023667D1
DE60023667D1 DE60023667T DE60023667T DE60023667D1 DE 60023667 D1 DE60023667 D1 DE 60023667D1 DE 60023667 T DE60023667 T DE 60023667T DE 60023667 T DE60023667 T DE 60023667T DE 60023667 D1 DE60023667 D1 DE 60023667D1
Authority
DE
Germany
Prior art keywords
polypeptides
seq
uro
another preferred
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023667T
Other languages
English (en)
Other versions
DE60023667T2 (de
Inventor
James Lipton
Anna Catania
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zengen Inc
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Application granted granted Critical
Publication of DE60023667D1 publication Critical patent/DE60023667D1/de
Publication of DE60023667T2 publication Critical patent/DE60023667T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Prostheses (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60023667T 1999-03-24 2000-03-23 C-terminale kpv polypeptiddimere und deren verwendung zur behandlung von urogenitalen störungen Expired - Lifetime DE60023667T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12623399P 1999-03-24 1999-03-24
US126233P 1999-03-24
PCT/US2000/007846 WO2000056353A2 (en) 1999-03-24 2000-03-23 A uro-genital condition treatment system

Publications (2)

Publication Number Publication Date
DE60023667D1 true DE60023667D1 (de) 2005-12-08
DE60023667T2 DE60023667T2 (de) 2006-08-10

Family

ID=22423735

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60036800T Expired - Lifetime DE60036800T2 (de) 1999-03-24 2000-03-17 Antimikrobielle aminosäuresequenzen aus alpha-melanocyten-stimulierendem hormon
DE60043358T Expired - Lifetime DE60043358D1 (de) 1999-03-24 2000-03-23 Alpha-MSH Peptide zur Behandlung von Urogenitale-Störungen
DE60023667T Expired - Lifetime DE60023667T2 (de) 1999-03-24 2000-03-23 C-terminale kpv polypeptiddimere und deren verwendung zur behandlung von urogenitalen störungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60036800T Expired - Lifetime DE60036800T2 (de) 1999-03-24 2000-03-17 Antimikrobielle aminosäuresequenzen aus alpha-melanocyten-stimulierendem hormon
DE60043358T Expired - Lifetime DE60043358D1 (de) 1999-03-24 2000-03-23 Alpha-MSH Peptide zur Behandlung von Urogenitale-Störungen

Country Status (14)

Country Link
EP (3) EP1191939B1 (de)
JP (2) JP4767418B2 (de)
KR (1) KR20020000791A (de)
CN (4) CN101249258A (de)
AT (3) ATE375801T1 (de)
AU (3) AU3629300A (de)
CA (2) CA2368387A1 (de)
CY (1) CY1107137T1 (de)
DE (3) DE60036800T2 (de)
DK (3) DK1191939T3 (de)
ES (3) ES2295016T3 (de)
HK (2) HK1040496B (de)
PT (2) PT1191939E (de)
WO (2) WO2000059527A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US6800291B1 (en) 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
EP1294740A2 (de) 2000-06-16 2003-03-26 Hercules Incorporated Chemisch modifizierte antimikrobielle peptide, zusammensetzungen sowie verfahren zu deren herstellung und verwendung
US6780838B2 (en) * 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
US7115574B2 (en) 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system
US6939846B2 (en) 2001-12-17 2005-09-06 Zengen, Inc. Use of a polypeptide for treatment of pruritis in animals
US7135548B2 (en) * 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
WO2004058804A1 (en) * 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
US20090232866A1 (en) * 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
US7674771B2 (en) 2003-10-29 2010-03-09 Toagosei Co., Ltd Antimicrobial peptides and utilization of the same
CN100390194C (zh) * 2004-02-27 2008-05-28 沛进生物科技股份有限公司 低溶血性的抗菌胜肽及其使用方法
JP4507080B2 (ja) 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
WO2006071822A1 (en) * 2004-12-23 2006-07-06 Regents Of The University Of Minnesota Exotoxin inhibitory factor
EP1849474B1 (de) 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimikrobielles peptid und verwendung davon
US8552042B2 (en) * 2006-05-12 2013-10-08 Christian Noe Use of combination preparations comprising antifungal agents
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
AU2008303922A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent
WO2009033812A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
JP5491396B2 (ja) * 2007-09-11 2014-05-14 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデフェンシンペプチドの使用
EP2508198B1 (de) 2011-04-07 2014-08-27 Fresenius Medical Care Deutschland GmbH Peptide zur Unterdrückung von Entzündungsreaktionen bei Hämodialyse
SE539566C2 (en) * 2014-09-03 2017-10-10 Danell Nils Device for the detection of gaseous amines from disease in the human urogential system
US10828015B2 (en) * 2018-07-12 2020-11-10 Prima-Temp, Inc. Vaginal temperature sensing apparatus and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422813A (de) * 1960-11-17 1966-10-31 Ciba Geigy Verfahren zur Herstellung neuer Polypeptide
CH444178A (de) * 1963-05-20 1967-09-30 Ciba Geigy Verfahren zur Herstellung von B-MSH
US5028592A (en) 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US5157023A (en) 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
AU597630B2 (en) * 1986-02-03 1990-06-07 University Patents Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
JP2633369B2 (ja) * 1988-03-28 1997-07-23 ブリティッシュ・テクノロジー・グループ・リミテッド ペプチド
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute

Also Published As

Publication number Publication date
DK1165120T3 (da) 2006-03-06
HK1040496B (zh) 2006-05-12
EP1433485A3 (de) 2004-09-22
CN1359300A (zh) 2002-07-17
CY1107137T1 (el) 2012-10-24
WO2000056353A3 (en) 2000-12-28
WO2000056353A2 (en) 2000-09-28
ATE375801T1 (de) 2007-11-15
CN1544461A (zh) 2004-11-10
EP1191939A1 (de) 2002-04-03
AU3772500A (en) 2000-10-09
HK1040496A1 (en) 2002-06-14
CA2368387A1 (en) 2000-10-12
CN100371019C (zh) 2008-02-27
CN101240017A (zh) 2008-08-13
ES2295016T3 (es) 2008-04-16
ATE308338T1 (de) 2005-11-15
PT1433485E (pt) 2010-02-03
AU2004242451A1 (en) 2005-01-20
DE60043358D1 (de) 2009-12-31
WO2000059527A1 (en) 2000-10-12
EP1433485B1 (de) 2009-11-18
JP2002541118A (ja) 2002-12-03
DE60023667T2 (de) 2006-08-10
HK1044287A1 (zh) 2002-10-18
JP2002542158A (ja) 2002-12-10
ES2251982T3 (es) 2006-05-16
AU776804B2 (en) 2004-09-23
ES2336661T3 (es) 2010-04-15
CN101249258A (zh) 2008-08-27
PT1191939E (pt) 2008-01-04
CA2367118A1 (en) 2000-09-28
DE60036800T2 (de) 2008-07-24
DK1433485T3 (da) 2010-03-29
EP1191939A4 (de) 2004-03-24
ATE448790T1 (de) 2009-12-15
EP1165120A2 (de) 2002-01-02
DK1191939T3 (da) 2008-02-11
JP4057787B2 (ja) 2008-03-05
AU776804C (en) 2005-06-23
KR20020000791A (ko) 2002-01-05
AU3629300A (en) 2000-10-23
EP1191939B1 (de) 2007-10-17
EP1165120B1 (de) 2005-11-02
JP4767418B2 (ja) 2011-09-07
EP1433485A2 (de) 2004-06-30
DE60036800D1 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DE60023667D1 (de) C-terminale kpv polypeptiddimere und deren verwendung zur behandlung von urogenitale störungen
ATE103176T1 (de) Gepufferte metronidazolmittel zur intravaginalen behandlung vaginaler infektionen.
ATE455526T1 (de) Nicht-hormonales vaginales verhütungsmittel
DE60023507D1 (de) Gerät zur behandlung von analer inkontinenz mit energieumwandlungseinrichtung
LV12452A (lv) Aktivas vielas vaginala ievadisanas sistema
DK1039858T3 (da) Medicinsk anordning
JP2004506482A5 (de)
ES2124225T3 (es) Tratamiento de la disfuncion erectil.
ATE437630T1 (de) Vorrichtung und methode zur behandlung von urininkontinenz bei frauen
RU2000108461A (ru) Вакцина против урогенитальных инфекций на основе вагинального суппозитория
Dayal et al. Disruption of the upper female reproductive tract epithelium by nonoxynol-9
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
SE9401620D0 (sv) The combined use of local anaesthetics and occlusive dressings
DE69131517T2 (de) Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz
EP0162726A3 (de) Gegen Virusinfektionen schützender natürlicher Hemmstoff
RU96108220A (ru) Способ комплексной лимфотропно-сорбционной терапии больных хроническим аднекситом, инфекционно-токсический вариант, неспецифической этиологии
CN1286964A (zh) 阴囊防护套
UA41100A (uk) Вагінальний супозиторій для лікування запальних захворювань піхви та вульви
Sharma et al. PENILE AGENESIS-ADOLESCENCE PRESENTATION
UA95691C2 (ru) Фармацевтическая вагинальная композиция и ее применение
CZ12396A3 (cs) Orální rouška
RU96106963A (ru) Способ комплексной лимфотропно-сорбционной терапии больных острыми неспецифическими воспалительными заболеваниями придатков матки
UA58330A (uk) Спосіб лікування рецидивів трихомонадно-хламідійної урогенітальної мікст-інфекції у чоловіків
UA37909A (uk) Спосіб діагностики супутньої інфекції у хворих на сифіліс
UA31546A (uk) Спосіб деривації сечі після цистектомії

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ZENGEN INC., CALABASAS, CALIF., US

8328 Change in the person/name/address of the agent

Representative=s name: SCHIEBER FARAGO, 80538 MUENCHEN

R082 Change of representative

Ref document number: 1165120

Country of ref document: EP

Representative=s name: SCHIEBER - FARAGO, 80538 MUENCHEN, DE